EMBOLEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EMBOLEX (EMBOLEX).
Low molecular weight heparin that potentiates antithrombin III, inhibiting factor Xa and factor IIa, thereby preventing thrombus formation.
| Metabolism | Primarily metabolized by desulfation and depolymerization in the liver; partial renal excretion. |
| Excretion | Renal: ~50% (10% as unchanged drug, 40% as inactive metabolites); Biliary/fecal: ~50% (primarily as metabolites). |
| Half-life | 2-3 hours (terminal half-life in healthy adults); prolonged in hepatic impairment and elderly. |
| Protein binding | 99% (primarily to albumin). |
| Volume of Distribution | 0.1-0.2 L/kg (low, indicating limited extravascular distribution primarily in blood). |
| Bioavailability | Oral: 60-75% (first-pass metabolism); Rectal: ~80%. IV: 100%. |
| Onset of Action | Oral: 30-60 minutes; Rectal: 30-60 minutes; IV: 5-10 minutes. |
| Duration of Action | 4-6 hours (single dose); longer with sustained-release formulations. |
Embolectomy with intra-arterial streptokinase: 250,000 IU loading dose over 30 minutes followed by 100,000 IU/hour for up to 72 hours. Alternatively, mechanical thrombectomy without thrombolytic.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment for renal impairment; use caution in severe renal impairment (CrCl <30 mL/min) due to increased bleeding risk. |
| Liver impairment | No specific adjustment for Child-Pugh class; use caution in severe hepatic impairment due to coagulopathy. |
| Pediatric use | Not established; use only if benefit outweighs risk, with careful monitoring. |
| Geriatric use | Increased risk of bleeding; consider lower doses and shorter infusion durations. No specific dosing guidelines; use clinical judgment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EMBOLEX (EMBOLEX).
| Breastfeeding | Excretion into human milk is unknown; low molecular weight heparins are unlikely to be absorbed by infant. M/P ratio not available. Use with caution in breastfeeding women. |
| Teratogenic Risk | Embolex (certoparin) is a low molecular weight heparin; no evidence of teratogenicity in animal studies. First trimester: Use only if clearly needed; no known fetal risk. Second and third trimesters: May be used; risk of bleeding in mother/fetus. Avoid near delivery due to risk of maternal hemorrhage and epidural hematoma. |
■ FDA Black Box Warning
Spinal or epidural hematomas may occur in patients receiving low molecular weight heparins and undergoing neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis.
| Serious Effects |
["Hypersensitivity to heparin or pork products","Active major bleeding","History of heparin-induced thrombocytopenia (HIT)","Known bleeding disorder","Severe uncontrolled hypertension"]
| Precautions | Risk of spinal/epidural hematoma with neuraxial interventions; increased risk of bleeding; heparin-induced thrombocytopenia (HIT); renal impairment; elderly; pregnancy. |
| Food/Dietary | Avoid alcohol; may increase risk of GI bleeding. No significant food interactions beyond GI irritation; taking with food may slow absorption but does not affect efficacy. |
Loading safety data…
| Fetal Monitoring |
| Monitor platelet count, anti-Xa levels if therapeutic dosing, signs of bleeding, blood pressure, fetal heart rate monitoring during labor if used near term. |
| Fertility Effects | No known adverse effects on fertility; heparin does not affect reproductive function in animal studies. |
| Clinical Pearls | EMBOLEX (meloxicam) is an NSAID with preferential COX-2 inhibition; use lowest effective dose for shortest duration to minimize GI and cardiovascular risks. Contraindicated in patients with active peptic ulcer disease, recent GI bleeding, or history of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs. Monitor renal function in elderly, dehydrated, or those on diuretics/ACE inhibitors. Not recommended for perioperative pain in CABG surgery. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Avoid alcohol while taking this medication. · Report signs of bleeding (black/tarry stools, coffee-ground vomit) or cardiovascular symptoms (chest pain, shortness of breath) immediately. · Do not take with other NSAIDs (including over-the-counter ibuprofen or naproxen). · Store at room temperature away from moisture and heat. |